Malignant Hyperthermia 2024

Edit Answers
1234567891011121314151617181920
Across
  1. 2. This type of drug should not be used when treating arrhythmias during an MH crisis
  2. 3. A non-inhaled triggering agent
  3. 4. To remove the volatile anesthetic and lower end-tidal CO2, ______ the patient with 100% oxygen
  4. 6. Any patient with this type of disorder should be closely monitored for signs of MH
  5. 7. This intervention should be avoided when treating the patient
  6. 8. Rhabdomyolysis associated with MH causes
  7. 9. The drug of choice to treat MH
  8. 14. One of the first signs of MH is an increase in this
  9. 17. Malignant Hyperthermia often occurs with activating agent
  10. 18. this is emergently inserted to obtain serial blood gases
  11. 19. The amount of diluent used to mix dantrolene
  12. 20. This is often a triggering agent in children
Down
  1. 1. Anesthesia providers ask about this when interviewing a patient
  2. 5. These measures are implemented as soon as possible to save the patient
  3. 10. The only safe inhalation agent used for a patient with MH
  4. 11. Another early sign of MH
  5. 12. Dantrolene should be prepared with this
  6. 13. The metabolite released from muscles that causes MH
  7. 15. This type of rigidity is the severe, sustained contracture of the jaw muscles after administration of succinylcholine
  8. 16. Untreated MH can lead to this complication